REFERENCES
1. Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, et al; ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2017;38:2739-91.
2. Ennezat PV, Maréchaux S, Pibarot P, Le Jemtel TH. Secondary mitral regurgitation in heart failure with reduced or preserved left ventricular ejection fraction. Cardiology 2013;125:110-7.
3. Inciardi RM, Rossi A, Benfari G, Cicoira M. Fill in the gaps of secondary mitral regurgitation: a continuum challenge from pathophysiology to prognosis. Curr Heart Fail Rep 2018;15:106-15.
4. Iung B, Vahanian A. Prevalence and definition of secondary mitral regurgitation. In: Fattouch K, Lancellotti P, Angelini GD, editors. Secondary Mitral Valve Regurgitation. London: Springer; 2015. pp. 1-6.
5. Rossi A, Dini FL, Faggiano P, Agricola E, Cicoira M, et al. Independent prognostic value of functional mitral regurgitation in patients with heart failure. A quantitative analysis of 1256 patients with ischaemic and non-ischaemic dilated cardiomyopathy. Heart 2011;97:1675-80.
6. Grigioni F, Enriquez-Sarano M, Zehr KJ, Bailey KR, Tajik AJ. Ischemic mitral regurgitation: long-term outcome and prognostic implications with quantitative Doppler assessment. Circulation 2001;103:1759-64.
7. Lancellotti P, Troisfontaines P, Toussaint AC, Pierard LA. Prognostic importance of exercise-induced changes in mitral regurgitation in patients with chronic ischemic left ventricular dysfunction. Circulation 2003;108:1713-7.
8. Lancellotti P, Tribouilloy C, Hagendorff A, Popescu BA, Edvardsen T, et al; Scientific Document Committee of the European Association of Cardiovascular Imaging. Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2013;14:611-44.
9. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2017;70:252-89.
10. Patel JB, Borgeson DD, Barnes ME, Rihal CS, Daly RC, et al. Mitral regurgitation in patients with advanced systolic heart failure. J Card Fail 2004;10:285-91.
11. Grayburn PA, Appleton CP, DeMaria AN, Greenberg B, Lowes B, et al; BEST Trial Echocardiographic Substudy Investigators. Echocardiographic predictors of morbidity and mortality in patients with advanced heart failure: the Beta-blocker Evaluation of Survival Trial (BEST). J Am Coll Cardiol 2005;45:1064-71.
12. Grayburn PA, Carabello B, Hung J, Gillam LD, Liang D, et al. Defining “severe” secondary mitral regurgitation: emphasizing an integrated approach. J Am Coll Cardiol 2014;64:2792-801.
13. Feldman T, Kar S, Elmariah S, Smart SC, Trento A, et al; EVEREST II Investigators. Randomized comparison of percutaneous repair and surgery for mitral regurgitation: 5-year results of EVEREST II. J Am Coll Cardiol 2015;66:2844-54.
14. Obadia JF, Messika-Zeitoun D, Leurent G, Iung B, Bonnet G, et al; MITRA-FR Investigators. Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med 2018;379:2297-306.
15. Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, et al; COAPT Investigators. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med 2018;379:2307-18.
16. Feldman T, Foster E, Glower DD, Kar S, Rinaldi MJ, et al; EVEREST II Investigators. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med 2011;364:1395-406.
17. Capodanno D, Tamburino C. Antithrombotic strategies in valvular and structural heart disease interventions: current status and future directions. Interv Cardiol Clin 2013;2:635-42.
18. Geis N, Raake P, Kiriakou C, Mereles D, Frankenstein L, et al. Temporary oral anticoagulation after MitraClip - a strategy to lower the incidence of post-procedural stroke? Acta Cardiol 2020;75:61-7.
19. Seeger J, Markovic S, Kessler M, Rottbauer W, Wöhrle J. Apixaban after percutaneous Edge-to-Edge mitral valve repair in patients with maintained sinus rhythm. JACC Cardiovasc Interv 2019;12:214-6.
20. Maisano F, Franzen O, Baldus S, Schäfer U, Hausleiter J, et al. Percutaneous mitral valve interventions in the real world: early and 1-year results from the ACCESS-EU, a prospective, multicenter, nonrandomized post-approval study of the MitraClip therapy in Europe. J Am Coll Cardiol 2013;62:1052-61.
21. Nickenig G, Estevez-Loureiro R, Franzen O, Tamburino C, Vanderheyden M, et al; Transcatheter valve treatment sentinel registry investigators of the EURObservational research programme of the european society of cardiology. Percutaneous mitral valve edge-to-edge repair: in-hospital results and 1-year follow-up of 628 patients of the 2011-2012 Pilot European Sentinel Registry. J Am Coll Cardiol 2014;64:875-84.
22. Grayburn PA, Sannino A, Packer M. Proportionate and disproportionate functional mitral regurgitation: a new conceptual framework that reconciles the results of the MITRA-FR and COAPT trials. JACC Cardiovasc Imaging 2019;12:353-62.
23. Lim DS, Kar S, Spargias K, Kipperman RM, O’Neill WW, et al. Transcatheter valve repair for patients with mitral regurgitation: 30-day results of the CLASP study. JACC Cardiovasc Interv 2019;12:1369-78.
24. Mazimba S, Lim SD, Kipperman R, Spargias K, Kar S, et al. Six-month outcomes from the multicenter, prospective study with the novel PASCAL Transcatheter Valve Repair System for Patients with Mitral Regurgitation in the CLASP Study. J Card Fail 2019;25:S6.
25. Kar S, Ng M, Lim S, Walters D, Webb J, et al. TCT-91 1-year outcomes from the multicenter, prospective study with the novel PASCAL transcatheter valve repair system for patients with mitral regurgitation in the CLASP study. J Am Coll Cardiol 2019;74:B91.
